文献速递抗栓抗凝管理药物不良反应与药物警戒

下肢关节置换或翻修术后不同剂量阿司匹林的出血比较:回顾性分析

A Retrospective Analysis Comparing Post-Operative Bleeding with Various Doses of Aspirin after Lower Extremity Joint Arthroplasty or Revision.
PubMed 文献 · Pharmacotherapy · 2021-06-18

该回顾性多中心队列研究纳入53,848例下肢关节置换或翻修术后接受阿司匹林预防血栓的患者,比较每日81、162、325、650 mg剂量组术后出血与静脉血栓栓塞的 odds。结果显示各剂量组间出血和VTE的 odds 均无统计学显著差异。

要点

  • 各阿司匹林剂量组术后出血 odds 无显著差异。
  • 各阿司匹林剂量组静脉血栓栓塞 odds 无显著差异。
  • 研究未发现某一剂量在出血或血栓方面更优。

核心结论

  • 在下肢关节置换或翻修术后接受阿司匹林血栓预防的患者中,所研究的各阿司匹林剂量组间出血和静脉血栓栓塞的 odds 均无统计学显著差异。

研究设计与样本

  • 为期3年的回顾性多中心队列研究,覆盖美国及其领土。
  • 纳入因全髋或全膝关节置换或翻修入院并接受预防性阿司匹林治疗的患者。
  • 共纳入53,848例接受阿司匹林的患者,按每日总剂量分为81、162、325、650 mg组。
  • 分析术后住院期间及术后40天内的出血和血栓栓塞事件。

主要发现

  • 出血发生于466例(0.87%)患者,静脉血栓栓塞发生于209例(0.39%)患者。
  • 以650 mg为参照,81 mg组出血 OR 1.12(95% CI 0.83-1.51,p=0.451)。
  • 以650 mg为参照,162 mg组出血 OR 0.83(95% CI 0.67-1.03,p=0.097)。
  • 以650 mg为参照,325 mg组出血 OR 0.83(95% CI 0.59-1.13,p=0.245)。
  • 以650 mg为参照,81 mg组VTE OR 0.71(95% CI 0.40-1.17,p=0.181);162 mg组 OR 0.75(95% CI 0.54-1.03,p=0.072);325 mg组 OR 1.00(95% CI 0.64-1.53,p=0.989)。

临床怎么用

  • 临床可依据患者个体情况选择阿司匹林剂量进行术后血栓预防,本研究中各剂量在出血和VTE风险上无显著差异。

局限性

  • 回顾性研究设计可能存在混杂和选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: Previous studies have shown that aspirin is noninferior to other anticoagulation therapies in preventing postoperative venous thromboembolism following lower extremity arthroplasty or revision; however, its optimal dosing for this indication is less clear. This study aims to compare the odds of bleeding between different aspirin dosages following lower extremity joint arthroplasty or revision. DESIGN: This is a 3-year retrospective multi-center cohort study across the United States and its territories. SETTING: This study included patients admitted for total hip or knee arthroplasty or revision and were treated with prophylactic aspirin. PATIENTS, INTERVENTION, MEASUREMENTS: Patients were assigned to groups based on a total daily aspirin dose of 81, 162, 325, or 650 mg. Data were analyzed for postsurgical bleeding and thromboembolism events occurring during the initial admission and up to 40 days following surgery. Other exploratory variables included type of surgery, hip or knee arthroplasty, length of stay, and patient demographic data. MAIN RESULTS: Among 53,848 patients receiving aspirin, 3922 received a total daily dose of 81 mg, 19,341 received a total daily dose of 162 mg, 5256 received a total daily dose of 325 mg, and 25,329 received a total daily dose of 650 mg. Bleeding occurred in 466 (0.87%) patients and venous thromboembolism (VTE) in 209 patients (0.39%). The odds of bleeding were compared using logistic regression, with the 650-mg dose as the reference group. None were statistically significant for bleeding between all studied aspirin doses: 81 mg (OR 1.12, 95% CI 0.83-1.51, p = 0.451), 162 mg (OR 0.83, 95% CI 0.67-1.03, p = 0.097), and 325 mg (OR 0.83, 95% CI 0.59-1.13, p = 0.245). The odds of VTE were also not statistically significant: 81 mg (OR 0.71, 95% CI 0.40-1.17, p = 0.181), 162 mg (OR 0.75 95% CI 0.54-1.03, p = 0.072), and 325 mg (OR 1.00, 95% CI 0.64-1.53, p = 0.989). CONCLUSIONS: There were no significant differences in the odds of bleeding or venous thromboembolism among all studied aspirin dosages in patients receiving aspirin for thromboprophylaxis following lower extremity joint arthroplasty or revision.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Watts PJ, Kopstein M, Harkness W, et al. A Retrospective Analysis Comparing Post-Operative Bleeding with Various Doses of Aspirin after Lower Extremity Joint Arthroplasty or Revision. Pharmacotherapy. 2021. PMID: 34050970. doi:10.1002/phar.2598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。